ANHUI HUAHENG BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121 CNY | -2.22% |
|
+2.16% | -3.91% |
| Apr. 22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
| Apr. 22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
Ratings chart - Surperformance
Sector: Food Processing
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -3.91% | 2.63B | - | ||
| +2.37% | 29.86B | B- | ||
| +20.02% | 24.81B | B | ||
| +6.21% | 11.19B | B- | ||
| +18.74% | 5.44B | C- | ||
| +20.42% | 4.54B | B+ | ||
| -9.27% | 3.79B | C | ||
| +4.52% | 3.12B | C+ | ||
| +29.28% | 2.86B | C+ | ||
| +4.70% | 2.41B | C- |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 688639 Stock
- Ratings Anhui Huaheng Biotechnology Co., Ltd.